{
  "asset": "JNJ-0683 (ARX788)",
  "query_terms": [
    "JNJ-0683 (ARX788)",
    "ARX788",
    "JNJ-0683"
  ],
  "returned_unique": 12,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT06224673",
      "title": "Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "HER2 Low Breast Carcinoma",
        "Triple Negative Breast Cancer",
        "Hormone-receptor-positive Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma"
      ],
      "lead_sponsor": "Laura Huppert, MD, BA",
      "collaborators": [
        "Ambrx, Inc."
      ],
      "interventions": [
        "ARX788",
        "Computed Tomography (CT)",
        "Biospecimen Collection",
        "Amiloride"
      ],
      "last_update": "2025-12-17",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06224673"
    },
    {
      "nct_id": "NCT04829604",
      "title": "A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "HER2 Positive Metastatic Breast Cancer"
      ],
      "lead_sponsor": "Ambrx, Inc.",
      "collaborators": [],
      "interventions": [
        "ARX788"
      ],
      "last_update": "2025-11-14",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04829604"
    },
    {
      "nct_id": "NCT05426486",
      "title": "A Randomized, Open Label, Multi-center Phase II-III Neoadjuvant Study Comparing the Efficacy and Safety of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) in Patients With HER2-positive Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "lead_sponsor": "Caigang Liu",
      "collaborators": [],
      "interventions": [
        "ARX788",
        "Pyrotinib maleate",
        "Trastuzumab",
        "Pertuzumab",
        "Docetaxel",
        "Carboplatin"
      ],
      "last_update": "2024-10-30",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05426486"
    },
    {
      "nct_id": "NCT03255070",
      "title": "A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression",
      "overall_status": "COMPLETED",
      "phase": "Phase 1",
      "conditions": [
        "Breast Neoplasms",
        "Gastric Neoplasm",
        "Solid Tumors"
      ],
      "lead_sponsor": "Ambrx, Inc.",
      "collaborators": [],
      "interventions": [
        "ARX788"
      ],
      "last_update": "2024-02-01",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03255070"
    },
    {
      "nct_id": "NCT06578286",
      "title": "Evaluate the Efficacy and Safety of ARX788 in Patients With HER2-positive Advanced Breast Cancer Whose Disease Has Progressed Following T-DXd Therapy",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Breast Cancer"
      ],
      "lead_sponsor": "Fudan University",
      "collaborators": [],
      "interventions": [
        "ARX788"
      ],
      "last_update": "2024-08-29",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06578286"
    },
    {
      "nct_id": "NCT05041972",
      "title": "A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors",
      "overall_status": "WITHDRAWN",
      "phase": "Phase 2",
      "conditions": [
        "HER2 Mutation-Related Tumors",
        "HER2 Amplified Solid Tumors"
      ],
      "lead_sponsor": "Ambrx, Inc.",
      "collaborators": [],
      "interventions": [
        "ARX788"
      ],
      "last_update": "2022-09-13",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05041972"
    },
    {
      "nct_id": "NCT05018676",
      "title": "A Single-arm, Single-center Phase II Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-AS269 Conjugate (ARX788) in the Treatment of Unresectable and/or Metastatic Breast Cancer With Low Expression of HER2",
      "overall_status": "UNKNOWN",
      "phase": "Phase 2",
      "conditions": [
        "Breast Cancer With Low Expression of HER2"
      ],
      "lead_sponsor": "Fudan University",
      "collaborators": [],
      "interventions": [
        "ARX788"
      ],
      "last_update": "2022-04-25",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05018676"
    },
    {
      "nct_id": "NCT05018702",
      "title": "A Prospective, Single-arm, Single-center Phase II Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-AS269 Conjugate (ARX788) in the Treatment of HER2-positive Breast Cancer Patients With Brain Metastases",
      "overall_status": "UNKNOWN",
      "phase": "Phase 2",
      "conditions": [
        "HER2-positive, Metastatic Breast Cancer"
      ],
      "lead_sponsor": "Fudan University",
      "collaborators": [],
      "interventions": [
        "ARX788"
      ],
      "last_update": "2022-06-01",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05018702"
    },
    {
      "nct_id": "NCT06663748",
      "title": "Evaluate the Efficacy and Safety of ARX788 Given Every 6 Weeks in Patients with HER2-positive Advanced Breast Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "HER2-positive, Metastatic Breast Cancer"
      ],
      "lead_sponsor": "Henan Cancer Hospital",
      "collaborators": [],
      "interventions": [
        "ARX788"
      ],
      "last_update": "2024-10-29",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06663748"
    },
    {
      "nct_id": "NCT02512237",
      "title": "A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression",
      "overall_status": "TERMINATED",
      "phase": "Phase 1",
      "conditions": [
        "Breast Neoplasms",
        "Stomach Neoplasms"
      ],
      "lead_sponsor": "Zhejiang Medicine Co., Ltd.",
      "collaborators": [
        "Ambrx, Inc."
      ],
      "interventions": [
        "ARX788"
      ],
      "last_update": "2020-06-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02512237"
    }
  ]
}